Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Public ClinicalTrials.gov record NCT03871829. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment
Study identification
- NCT ID
- NCT03871829
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 88 participants
Conditions and interventions
Conditions
Interventions
- Carfilzomib 20 mg/m^2 Drug
- Carfilzomib 70 mg/m^2 Drug
- Dexamethasone 40 mg Drug
- Dara-SC 1800 mg Drug
- Dexamethasone 20 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2019
- Primary completion
- Oct 23, 2022
- Completion
- Jan 9, 2023
- Last update posted
- Mar 29, 2025
2019 – 2023
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Oncology Institute of Hope and Innovation | Tucson | Arizona | 85745 | — |
| American Institute of Research (AIR) | Whittier | California | 90603 | — |
| Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne | Indiana | 46804 | — |
| Karmanos Cancer Institute - Wayne State University | Detroit | Michigan | 48201 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110-1032 | — |
| Weill Medical College of Cornell University | New York | New York | 10065 | — |
| Cleveland Clinic Main Campus | Cleveland | Ohio | 44195 | — |
| Baylor Scott and White Health | Dallas | Texas | 75246 | — |
| Millennium Oncology | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03871829, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03871829 live on ClinicalTrials.gov.